Antidepressant Augmentation Strategies: Evidence-Based Options When First-Line Treatment Falls Short

Roughly 50–60% of patients with major depressive disorder do not achieve full remission with their first antidepressant trial. The STAR*D study demonstrated that after an adequate trial of citalopram, only 36.8% of participants remitted. This leaves clinicians with two broad options: switching to a different antidepressant or augmenting the current one with a second agent.

Augmentation is generally preferred when:

• The patient has achieved a partial response (≥25% improvement in depression scores) — switching risks losing those gains
• The current antidepressant is well-tolerated
• The patient has been on an adequate dose for at least 4–6 weeks

Switching is typically favored when:

• There has been no meaningful response after an adequate trial
• Side effects are intolerable
• The patient prefers monotherapy

Before pursuing either path, clinicians should verify the trial was genuinely adequate — many so-called treatment failures reflect subtherapeutic dosing, poor adherence, or insufficient duration. Dose optimization remains the single most overlooked step in treatment-resistant depression management. Only after confirming an adequate trial should augmentation strategies be systematically considered.

Lithium augmentation carries the longest track record and the deepest evidence base of any augmentation strategy. Meta-analyses encompassing over 10 randomized controlled trials show lithium augmentation produces response rates roughly 2–3 times higher than placebo when added to tricyclics or SSRIs. Target serum levels for augmentation are typically 0.6–0.8 mEq/L, lower than those used in bipolar disorder. Response often emerges within 2–4 weeks.

Benefits: Strong evidence base, anti-suicidal properties, well-characterized pharmacology.
Risks: Requires blood monitoring (renal function, thyroid, serum levels), narrow therapeutic index, weight gain, tremor, polyuria, and long-term nephrotoxicity risk. These monitoring demands have made lithium underused in current practice despite its robust efficacy data.

Triiodothyronine (T3) augmentation at doses of 25–50 mcg/day has moderate evidence from several controlled trials. The STAR*D trial found T3 augmentation modestly effective at step 3, with a remission rate of 24.7%. T3 is generally well-tolerated, with a favorable side effect profile compared to lithium — no blood level monitoring is required.

Benefits: Simple dosing, few drug interactions, generally well-tolerated.
Risks: Tachycardia, potential bone density effects with prolonged use, limited data beyond 8–12 weeks. Evidence strength is moderate, weaker than lithium's.

Three atypical antipsychotics carry FDA approval specifically for adjunctive treatment of major depressive disorder: aripiprazole (2–15 mg/day), quetiapine XR (150–300 mg/day), and brexpiprazole (1–3 mg/day). This represents the best-powered augmentation evidence available, drawn from large industry-sponsored RCTs involving thousands of patients.

Aripiprazole is the most studied, with multiple trials showing a mean improvement of approximately 3 points over placebo on the MADRS. Number needed to treat (NNT) is roughly 7–9. It carries a relatively favorable metabolic profile among atypicals but commonly causes akathisia (up to 25% of patients) and restlessness.

Quetiapine XR has comparable efficacy data and may benefit patients with prominent insomnia or anxiety. However, it carries more substantial metabolic risks — weight gain averaging 1–2 kg in 6-week trials, sedation, and lipid elevations.

Brexpiprazole offers a profile similar to aripiprazole with potentially lower akathisia rates, though head-to-head comparisons are lacking.

Key concern: All atypical antipsychotics carry risks of tardive dyskinesia with long-term use, metabolic syndrome, and weight gain. The clinical question is whether these risks are proportionate when treating depression — particularly given the absence of long-term augmentation data beyond 6–12 months for most trials.

Bupropion combination — adding bupropion (150–300 mg/day) to an SSRI or SNRI — is among the most widely used augmentation strategies in clinical practice. Its pharmacologic rationale is sound: bupropion adds norepinephrine and dopamine reuptake inhibition to serotonergic agents and may counteract SSRI-induced sexual dysfunction and fatigue. However, the CO-MED trial found no significant difference in remission rates between SSRI monotherapy and SSRI + bupropion combination at 12 weeks. Despite this, bupropion combination remains popular due to its tolerability and absence of weight gain.

Mirtazapine combination (15–45 mg/day added to an SSRI/SNRI) exploits mirtazapine's distinct mechanism — noradrenergic and specific serotonergic action, plus 5-HT2 and 5-HT3 antagonism. The combination targets insomnia and appetite loss effectively. Evidence strength is moderate; the CO-MED trial showed a trend favoring this combination over monotherapy but did not reach statistical significance. Primary concerns are sedation and weight gain (averaging 2–3 kg).

Buspirone augmentation (15–60 mg/day) has been used for decades, but evidence is the weakest in this category. The STAR*D trial found buspirone augmentation at step 2 yielded a remission rate of 30.1%, numerically lower than bupropion augmentation (39.0%), though the comparison was not randomized. Buspirone's mild anxiolytic properties may help specific patients, but it should not be considered a first-line augmentation agent.

Psychostimulant augmentation with methylphenidate or modafinil targets residual fatigue, cognitive slowing, and anhedonia. Evidence is limited to small trials with mixed results. A meta-analysis of modafinil augmentation showed modest benefit for residual fatigue and sleepiness, but effect sizes on core depressive symptoms were small. Lisdexamfetamine has been studied in treatment-resistant depression with negative Phase III results. Stimulants may be appropriate in select cases — particularly elderly patients with apathy or those with comorbid ADHD — but carry risks of dependence, insomnia, appetite suppression, and cardiovascular effects.

Ketamine and esketamine represent a genuinely novel mechanism — NMDA receptor antagonism and downstream effects on AMPA receptors and BDNF signaling. IV ketamine (0.5 mg/kg over 40 minutes) produces rapid antidepressant effects within hours in approximately 50–70% of treatment-resistant patients. Esketamine (Spravato), the S-enantiomer nasal spray, received FDA approval in 2019 for treatment-resistant depression.

Evidence strength is strong for acute response but limited for sustained benefit. Effects typically wane within 1–2 weeks without repeated dosing. Risks include dissociation, elevated blood pressure, nausea, and concerns about long-term cognitive and urological effects. Esketamine requires REMS-certified administration settings with 2-hour post-dose monitoring. Cost and access remain significant barriers.

The following stepwise approach synthesizes current evidence and clinical pragmatism:

1. Confirm adequacy of the current trial: therapeutic dose, sufficient duration (6–8 weeks), verified adherence
2. First-line augmentation choices (choose based on patient profile):
   • Aripiprazole (2–5 mg) — strongest regulatory evidence, watch for akathisia
   • Bupropion (150–300 mg) — best option when fatigue, low motivation, or sexual dysfunction are prominent; favorable side effect profile despite modest RCT data
   • Lithium (600–900 mg, target level 0.6–0.8) — strongest independent evidence base, particularly when suicidality is a concern; requires lab monitoring
3. Second-line options:
   • Mirtazapine — when insomnia and weight loss are prominent
   • Quetiapine XR — when anxiety and insomnia dominate
   • T3 (25–50 mcg) — when other options are contraindicated or not tolerated
4. Third-line/specialist options:
   • Esketamine — for formally defined treatment-resistant depression (failure of ≥2 adequate trials)
   • Stimulant augmentation — selected cases with residual fatigue/cognitive symptoms

At every step, reassess whether psychotherapy — particularly cognitive behavioral therapy or behavioral activation — has been adequately integrated. Augmentation pharmacology works best within a broader treatment framework, not as a standalone fix.